Bleomycin a2

Base Information

• Chemical Name: Bleomycin a2
• CAS No.: 11056-06-7
• Deprecated CAS: 1247874-09-4,69215-21-0,754126-85-7
• Molecular Weight: 2927.17
• European Community (EC) Number: 232-925-2,234-356-5,689-127-6
• DSSTox Substance ID: DTXSID20872327
• Nikkaji Number: J25.633A
• Wikipedia: Bleomycin
• Wikidata: Q26841044
• NCI Thesaurus Code: C311,C313,C312
• RXCUI: 1621,1622
• Metabolomics Workbench ID: 133738
• ChEMBL ID: CHEMBL403664
• Mol file: 11056-06-7.mol

Synonyms:Bellon, Bléomycine;Bléomycine Bellon;Blanoxan;Blenoxane;BLEO cell;BLEO-cell;BLEOcell;Bleolem;Bleomicina;Bleomycin;Bleomycin A(2);Bleomycin A2;Bleomycin B(2);Bleomycin B2;Bleomycin Sulfate;Bleomycins;Bleomycinum Mack;Mack, Bleomycinum;Sulfate, Bleomycin

Chemical Property of Bleomycin a2

Chemical Property:

• Appearance/Colour: powder
• PSA: 794.66000
• LogP: -1.89040
• Storage Temp.: 2-8°C
• Solubility.: H2O: 20 mg/mL
• Water Solubility.: Soluble
• XLogP3: -7.5
• Hydrogen Bond Donor Count: 20
• Hydrogen Bond Acceptor Count: 31
• Rotatable Bond Count: 36
• Exact Mass: 1414.51898128
• Heavy Atom Count: 96
• Complexity: 2580

Purity/Quality:

99%, ^*data from raw suppliers

BLEOMYCIN 95.00% ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T
• Hazard Codes: T
• Statements: 46-40
• Safety Statements: 53-36/37-45

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
• Isomeric SMILES: CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
• Recent ClinicalTrials: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
• Recent EU Clinical Trials: Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic cancer' (IREC).
• Recent NIPH Clinical Trials: International Clinical Trial of Low and Standard Risk Germ Cell Tumors; AGCT1531
• Description: Bleomycin is a complex of no less than 16 glycopeptide antibiotics made from the family Streptomyces verticilus, which have different R groups. Bleomycines exhibit antitumor, antiviral, and antibacterial activity. When bound to DNA, they disturb the spiraling of both single and double strands of DNA. To a lesser degree, they inhibit RNA and protein synthesis. It is administered both intravenously and intramuscularly.
• Uses: It is used for lymphomas, carcinomas, and sarcomas. Bleomycin sulfate USP (Blenoxane)is used to traet squamous cell carcinoma of head, neck, esophagus, skin, GU tract; testicular tumor; Hodgkin’s lymphomas. Antineoplastic for solid tumors.
• Indications: The bleomycins are a group of glycopeptides that are isolated from Streptomyces verticillus. The clinical preparation, bleomycin sulfate (Blenoxane), is a mixture of several components. Bleomycin binds to DNA, in part through an intercalation mechanism, without markedly altering the secondary structure of the nucleic acid. The drug produces both single- and double-strand scission and fragmentation of DNA. It is thought that the bleomycins, which are avid metal-chelating agents, form a bleomycin–Fe ++ complex that can donate electrons to molecular oxygen, thus forming the superoxide and hydroxyl free radicals. It is these highly reactive intermediates that attack DNA and produce DNA strand breakage and maximum cytotoxicity in the late G2 and early M-phases of the cell cycle.
• Therapeutic Function: Antibiotic
• Clinical Use: Bleomycin, in combination with cisplatin or etoposide, is important as part of the potentially curative combination chemotherapy of advanced testicular carcinomas. Bleomycin is used in some standard regimens for the treatment of Hodgkin’s and non-Hodgkin’s lymphomas, and it is useful against squamous cell carcinomas of the head and neck, cervix, and skin.
• Drug interactions: Potentially hazardous interactions with other drugs Antipsychotics: avoid clozapine, increased risk of agranulocytosis. Cytotoxics: increased pulmonary toxicity with cisplatin and brentuximab, avoid with brentuximab; in combination with vinca alkaloids can lead to Raynaud’s syndrome and peripheral ischaemia. Live vaccines: avoid concomitant use.

Technology Process of Bleomycin a2

There total 1 articles about Bleomycin a2 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ bleomycin (11056-06-7,9041-93-4)

Guidance literature:

Refernces

• 1、 -. "Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same". . . Retrieved 2010/05/13.
• 2、 -. "Compositions containing piperine". . . Retrieved 2008/06/13.